Concord Biotech · NSE: CONCORDBIO · BSE: 543960

Q4 FY26 results · Jan–Mar 2026

Concord Biotech reported revenue from operations of ₹326.08 crore (down 24.1% from Q4 FY25) and net profit of ₹88.47 crore (down 37.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ
Revenue from operations	326.08	429.88	−24.1%	277.77	+17.4%
Other income	15.35	9.38	+63.6%	9.98	+53.9%
Total income	341.43	439.27	−22.3%	287.74	+18.7%
Profit before share of associates & JVs and tax	114.25	185.09	−38.3%	86.85	+31.5%
Share of profit/(loss) of associates & JVs	(0.18)	(1.55)		(0.70)
Net profit for the period	88.47	140.39	−37.0%	63.64	+39.0%
Attributable to shareholders of the company	88.79	140.39	−36.8%	64.48	+37.7%
EPS, basic (₹)	8.46	13.42	−37.0%	6.08	+39.1%
Net margin (%)	27.1	32.7		22.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ
Revenue from operations	325.89	429.88	−24.2%	278.13	+17.2%
Other income	15.54	9.38	+65.6%	10.08	+54.1%
Total income	341.43	439.27	−22.3%	288.22	+18.5%
Profit before tax	118.38	185.09	−36.0%	90.30	+31.1%
Net profit for the period	90.02	141.94	−36.6%	67.78	+32.8%
EPS, basic (₹)	8.60	13.57	−36.6%	6.48	+32.7%
Net margin (%)	27.6	33.0		24.4

Consolidated

Filed with BSE: 29 May 2026, 18:55 IST
Board meeting: 29 May 2026
Period: 01 Jan 2026 to 31 Mar 2026
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 May 2026, 18:55 IST
Board meeting: 29 May 2026
Period: 01 Jan 2026 to 31 Mar 2026
Review status: Audited
Source: XBRL filing on BSE